Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC) Meeting Abstract


Authors: Tannir, N. M.; Fan, A. C.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Meric-Bernstam, F.; DeMichele, A.; Voss, M. H.; Harding, J. J.; Srinivasan, R.; Shapiro, G.; Telli, M. L.; Munster, P. N.; Carvajal, R. D.; Jenkins, Y.; Whiting, S. H.; Bendell, J. C.; Bauer, T. M.
Abstract Title: Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC)
Meeting Title: 2018 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 6 Suppl.
Meeting Dates: 2018 Feb 8-10
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-20
Language: English
ACCESSION: WOS:000436179500597
DOI: 10.1200/JCO.2018.36.6_suppl.603
PROVIDER: wos
Notes: Meeting Abstract: 603 -- Source: Wos
Altmetric Score
MSK Authors
  1. James Joseph Harding
    64 Harding
  2. Martin Henner Voss
    122 Voss